% | $
Quotes you view appear here for quick access.

Advaxis, Inc. Message Board

  • picdoc501 picdoc501 May 2, 2011 11:55 PM Flag

    All You Need To Know in One Post

    I hope everyone is ready (including bashers).... because I'm about to drop some serious knowledge on your #$%$ The following are points I highlight when convincing friends and family to invest in ADXS.

    1) Phase I had 15 people in it, all with stage 4b cervical cancer (VERY SICK PEOPLE). They all received 2 doses of the vaccine when it was known that 3 doses is the actual therapeutic dose. Why only 2? Because the company was scared. This had never been tested on humans before. Still.... with just 2 doses, 3 of these patients lived 3 years and 2 are still living 4 years out! The historical median survival is 6 months! This trial had a median survival of close to 1 year! Imagine the results when 3 doses are given AND given in combination with chemo!!!

    2) Provenge extends life an average of 4 months, is difficult to administer, and will cost Medicare $93,000. Yet it was approved!! And for just 4 extra months of life!! Listeria based vaccines are easy to produce, easy to administer, potentially very efficacious, and will cost Medicare 15x (at least) less for reimbursement.

    3) Drugs fail to be FDA approved because they are dangerous. We know 72 patients...sick patients... have received the vaccine and no serious side effects were experienced.

    4) Provenge is a one trick pony. There are NINE Listeria constructs and who knows how many more cancers this can be applied to? The possibilities are literally infinite. Insert any antigen you desire. The vector (Listeria) will work the same way and elicit the same immune response. This could prove disasterous however if the technology DOESN'T work since one construct will give a glimpse into all the others. Please see point 1 for hints that it DOES work.

    5) ADXS management is brilliant. They have a phase 2 going on in CIN (pre-cervical cancer) AND Stage 4b cervical cancer. If it works in both, chances are this vaccine will be approved for ALL stages of cervical cancer. Provenge is only approved for late stage/metastatic prostate cancer.

    6) ADXS has collaborative agreements with NCI, CRUK, Dept of Homeland Security, Wister, etc. NCI and CRUK are running trials at their OWN EXPENSE. Organizations of this caliber do not associate with POS companies.

    7) Veterinary applications. If this thing ONLY works in cattle to prevent hoof and mouth disease we are looking at a $10 stock. Forget humans. There are millions of cattle worldwide and they are a commodity. Let's not forget about canine osteosarcoma as well.

    8) A lesson in pattern recognition. DNDN went as high as $54 and was the first immunotherapy approved. How high will the next approved immunotherapy go? No telling how high ADXS goes with 9 constructs and limitless constructs in the future. Imagine the kind of profit you can make by buying in NOW! And trust me... the cost effectiveness of Listeria based vaccines is a HUGE issue. Let's say ADXS vaccines extend life of prostate cancer patients 3 months and Provenge extends it 4 months. Guess which one will be reimbursed by Medicare. NOT Provenge. Why? Because 1 month of life is not worth an extra $90,000 to the government.

    9) Great business model. ADXS has never had a problem raising money. There is minimal dilution. And guess what? They have enough to make it to the end of phase 2. Forget phase 3. After good phase 2 results they license out the technology and collect big time!! Why is this good? Because it means the share price will move FAST and you won't have to wait very long before you are a millionaire.

    10) Advaxis has the only immunotherapy that downregulates T-regs. These T-reg cells help protect the tumor from immune attack. No other immune therapy dose this. And this is a big reason why Advaxis vaccines will work.

    Keep this post at the top for newbies and feel free to add.

    The doctor has spoken.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • bump

      Sentiment: Hold

    • bump

      Sentiment: Hold

    • Fantastic Post

      Sentiment: Strong Buy

    • Bumperoo

    • Didn't picdoc do an updated post like this? Did it include their new heavy hitter?


      Advaxis, Inc., (ADXS), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced the appointment of Daniel J. O’Connor to the position of Senior Vice President, Chief Legal and Business Development Officer.

      Thomas Moore, Advaxis’ Chairman and Chief Executive Officer, stated, “We are delighted to welcome Dan O’Connor to Advaxis. Now that our clinical development has reached an advanced stage, his success as a general counsel and in leading business development and licensing negotiations is a timely addition to our management team. We are very fortunate to attract a highly experienced professional of this caliber. It is a significant endorsement of Advaxis’ immunotherapy technology and our potential to unlock unrealized enterprise value.”

      Mr. O’Connor, age 48, has fifteen years of executive, legal, and regulatory experience in the biopharmaceutical industry with ImClone Systems, PharmaNet and Bracco Diagnostics.

      "I believe that Advaxis’ future holds tremendous potential," said Mr. O’Connor. "I look forward to continuing the company's culture of decisiveness and efficient execution. We will aggressively advance ADXS-HPV and our other pipeline product candidates, while building commercial alliances to both accelerate product development and generate shareholder value."

      Joining ImClone in 2003, Mr. O’Connor supported the clinical development, launch, and commercialization of ERBITUX(R). As ImClone’s senior vice president, general counsel, and secretary, he played a key role in resolving numerous issues facing ImClone, including extensive licensing negotiations, in advance of the company being sold to Eli Lilly in 2008.

      Prior to joining ImClone, Mr. O’Connor was PharmaNet’s general counsel and instrumental in building the company from a start-up contract research organization to an established world leader in clinical research. Mr. O’Connor was also a criminal prosecutor in New Jersey and gained leadership experience as a Captain in the U.S. Marines, serving in the Persian Gulf in 1990. Most recently, while at Bracco Diagnostics, a large private pharmaceutical and medical device company, Mr. O’Connor was the company’s vice president and general counsel.

    • If you know this why would institutions not be aware of it and be holding shares. Why are institutions not buying? Whay are insiders not buying at these levels? There must be a reason the stock is trading at $.07. I would like to buy what you are selling but the price action, institutional ownership and lack of insider buying say otherwise!

      Sentiment: Sell

    • bump

      Sentiment: Strong Buy

    • bump

      Sentiment: Strong Buy

    • BUMP

    • View More Messages
11.83+0.01(+0.08%)4:00 PMEDT